StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Friday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.29 on Friday. TherapeuticsMD has a 1 year low of $1.15 and a 1 year high of $3.07. The business has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $1.78.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP lifted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.